
Supplementary Materials for **Endoglin in circulation predicts favourable outcome for pemetrexed treatment in advanced non-small cell lung cancer**


Che-Hsing Li, MD; Jiunn-Liang Ko, PhD; Yu-Ping Hsiao, MD, PhD; Ming-Hung Tsai, MD; Yen-Chein Lai, PhD; I-Lun Hsin, PhD; Yu-Ting Kang, PhD; Gwo-Tarng Sheu, PhD; Ming-Fang Wu, MD, PhD\*

\*Corresponding author. Email: M.-F. W. (mfwu0111@gmail.com)

**Figures**

****

**Fig. S1** Effects of endoglin levels on pemetrexed prognosis in the cohort. Endoglin concentration (ng/mL) in patients with non-small cell lung cancer before pemetrexed treatment were measured using enzyme-linked immunosorbent assay. (A) Progression-free survival and (B) overall survival of groups with very high (> 30 ng/mL) and very low endoglin (< 20 ng/mL) were analysed using the Kaplan–Meier method and the log rank test.

****

**Fig. S2** Effects of epidermal growth factor receptor (*EGFR*) mutation on endoglin levels and survival. (A) Endoglin concentration (ng/mL) in patients with non-small cell lung cancer before pemetrexed treatment were measured using enzyme-linked immunosorbent assay. The endoglin levels in the *EGFR* wild type and mutation group were compared through unpaired t test. (B) Progression-free survival and (C) overall survival of groups with *EGFR* wild type and mutation were analysed using the Kaplan–Meier method and the log rank test.

**Tables**

**Table S1** Demographic data of patients with non-small cell lung cancer and treated with pemetrexed.

|  |  |  |
| --- | --- | --- |
| Factors |  | All patient  (n = 71) |
| Gender | Female | 38 (54%) |
| Male | 33 (46%) |
| Agea | < 65 | 46 (65%) |
| ≥ 65 | 25 (35%) |
| Pathological type | Adenocarcinoma | 69 (97%) |
| Othersb | 2 (3%) |
| Lymph node | N0 – N1 | 13 (18%) |
| N2 – N3 | 58 (82%) |
| ECOG PS | 0 – 1 | 56 (79%) |
| 2 | 15 (21%) |
| Smoking | Never | 45 (63%) |
| Active or quitted | 26 (37%) |
| Chemotherapy line | 1 | 54 (76%) |
| > 1 | 17 (24%) |
| Pemetrexed | Alone | 12 (17%) |
| Combinedc | 59 (83%) |
| EGFR status | Wild type | 33 (46%) |
| Mutation | 30 (41%) |
| Unknown | 8 (11%) |

ECOG PS, Eastern Cooperative Oncology Group Performance status. EGFR, epidermal growth factor receptor. a, age presents the patient’s age at baseline. b, other pathological types include squamous cell carcinoma and poorly differentiated carcinoma. c, pemetrexed is combined with platinum.